MAM
ALXN

Martingale Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Martingale Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,555
Closed -$310K – 1014
2017
Q1 		$310K Sell
2,555
-1,029
-29% -$133K ﹤0.01% 877
2016
Q4 		$439K Sell
3,584
-2,062
-37% -$252K 0.01% 845
2016
Q3 		$692K Sell
5,646
-1,318
-19% -$170K 0.01% 756
2016
Q2 		$814K Sell
6,964
-304
-4% -$43.1K 0.01% 570
2016
Q1 		$1.01M Sell
7,268
-2,961
-29% -$435K 0.02% 487
2015
Q4 		$1.95M Sell
10,229
-2,601
-20% -$454K 0.04% 310
2015
Q3 		$2.01M Buy
12,830
+1,360
+12% +$248K 0.05% 305
2015
Q2 		$2.07M Sell
11,470
-1,056
-8% -$182K 0.05% 323
2015
Q1 		$2.17M Buy
12,526
+200
+2% +$36.2K 0.05% 322
2014
Q4 		$2.28M Buy
12,326
+3,258
+36% +$604K 0.06% 305
2014
Q3 		$1.5M Buy
9,068
+1,100
+14% +$181K 0.05% 354
2014
Q2 		$1.25M Sell
7,968
-11
-0.1% -$1.74K 0.04% 440
2014
Q1 		$1.21M Buy
7,979
+126
+2% +$20K 0.04% 430
2013
Q4 		$1.04M Buy
7,853
+397
+5% +$47.6K 0.04% 521
2013
Q3 		$867K Sell
7,456
-3,900
-34% -$428K 0.03% 583
2013
Q2 		$1.05M Buy
+11,356
New +$1.09M 0.04% 463

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Martingale Asset Management's ALXN Position: Q2 2017 in Review

Martingale Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 2,555 shares — an estimated $310K sold.

Martingale Asset Management first reported a position in ALXN in Q2 2013 and held it in 16 quarters. The position peaked at $2.28M in Q4 2014. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Martingale Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Martingale Asset Management sold 2,555 Alexion Pharmaceuticals shares in Q2 2017, an estimated $310K.
  • Martingale Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Martingale Asset Management's Alexion Pharmaceuticals position peaked at $2.28M in Q4 2014.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Martingale Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.